Prosecution Insights
Prosecution Insights
7 pending office actions • 4 art units • 5 examiners • 0 of 7 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (14%) |
| §103 only | 1 (14%) |
| No statute on record | 5 (71%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 3 | 50.2% | +23.0% |
| TRAN, SUSAN T | 1 | 62.8% | +36.0% |
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.9% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.5% | +53.7% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19258712 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | WEDDINGTON, KEVIN E | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18179196 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | BARSKY, JARED | 128d overdue |
| 17571110 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | BARSKY, JARED | 127d overdue |
| 18601603 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | RAMACHANDRAN, UMAMAHESWARI | 112d overdue |
| 17541461 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | BARSKY, JARED | 22d overdue |
| 19270315 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | TRAN, SUSAN T | 5d |
| 18061091 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | VALENROD, YEVGENY | 22d |
| Art Unit | Apps |
|---|---|
| 1628 | 4 |
| 1615 | 1 |
| 1629 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19270315 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | TRAN, SUSAN T | 1615 | §103 | Final Rejection | 5d | Pending | Jul 15, 2025 |
| 19258712 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | WEDDINGTON, KEVIN E | 1629 | §101 | Non-Final OA | 21d | Pending | Jul 02, 2025 |
| 18601603 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | RAMACHANDRAN, UMAMAHESWARI | 1627 | Other | Final Rejection | 112d overdue | Pending | Mar 11, 2024 |
| 18179196 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | BARSKY, JARED | 1628 | Other | Final Rejection | 128d overdue | Pending | Mar 06, 2023 |
| 18061091 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | VALENROD, YEVGENY | 1628 | Other | Non-Final OA | 22d | Pending | Dec 02, 2022 |
| 17571110 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | BARSKY, JARED | 1628 | Other | Non-Final OA | 127d overdue | Pending | Jan 07, 2022 |
| 17541461 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | BARSKY, JARED | 1628 | Other | Final Rejection | 22d overdue | Pending | Dec 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial